Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Heinz Ludwig, Takashi Ikeda, Cesar O. Freytes, Koji Kawamura, Yoshiko Atsuta, Hiroyuki Takamatsu, David H. Vesole, Hari Parameswaran, Axel Hinke

Blood (2023) 142 (Supplement 1): 7100.

https://doi.org/10.1182/blood-2023-179105

Published: 2023

Journal Articles

Treatment Patterns and Clinical Outcomes Among Patients with Newly Diagnosed and Relapsed/Refractory Systemic Light Chain Amyloidosis

Huamao Mark Lin, PhD, Carl Victor Asche, MBA, MSc, PhD, Jinma Ren, PhD, Candice Yong, PhD, Hari Parameswaran, MD, Katarina Luptakova, Douglas Faller, MD, Brian Seal, RPh, MBA, PhD

Blood (2016) 128 (22): 3559.

https://doi.org/10.1182/blood.V128.22.3559.3559

Published: 2016

Journal Articles

Marizomib for CNS-Multiple Myeloma

Ashraf Z Badros, MD, Zeba Singh, MD, Binod Dhakal, MDMS, Young Kwok, MD, Ann MacLaren, PhD, Paul G. Richardson, MD, Mohit Trikha, PhD, Hari Parameswaran, MD

Blood (2016) 128 (22): 2118.

https://doi.org/10.1182/blood.V128.22.2118.2118

Published: 2016

Journal Articles

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Ehab Atallah, MD, Laura C Michaelis, MD, Karen B. Carlson, MD PhD, Anita D'Souza, MBBS, MD, Timothy S. Fenske, MD, Marcelo C. Pasquini, MD, Mehdi Hamadani, MD, Arielle Baim, Jessica Guhl, Hari Parameswaran, MD

Blood (2016) 128 (22): 5192.

https://doi.org/10.1182/blood.V128.22.5192.5192

Published: 2016

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

NARROW

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Treatment Patterns and Clinical Outcomes Among Patients with Newly Diagnosed and Relapsed/Refractory Systemic Light Chain Amyloidosis

Marizomib for CNS-Multiple Myeloma

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Email alerts

ASH Publications

American Society of Hematology

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Treatment Patterns and Clinical Outcomes Among Patients with Newly Diagnosed and Relapsed/Refractory Systemic Light Chain Amyloidosis

Marizomib for CNS-Multiple Myeloma

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only